


A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of Vorasidenib in Subjects with Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation



For additional details about Agios study AG881-C-004 (INDIGO), including the study design, study sites, or other information, please visit www.ClinicalTrials.gov (Identifier: NCT04164901) or contact Agios Medical Information: email: medinfo@agios.com; Phone: 833-228-8474.

Vorasidenib is an investigational agent. The efficacy and safety of vorasidenib have not been established. There is no guarantee that vorasidenib will receive health authority approval or become commercially available in any country for the use being investigated.